Improves hydration and supports energy levels
Document daily dose, injection site, and any side effects to maintain consistency and track tolerance
Despite these favorable mechanisms, concerns remain regarding the impact of GLP-1 RAs on lean body mass (LBM) and the potential risk of sarcopenia
It has now surpassed viral liver disease to become the worlds most common liver disease, increasing the imminence of more basic and clinical research
Furthermore, dual-action compounds engaging GLP-1 combined with glucose-dependent insulinotropic polypeptide (GIP) or glucagon pathways, alongside triple agonists incorporating all three receptors activation, have exhibited enhanced therapeutic potential
Guevara-Aguirre J, Guevara A, Palacios I, Prez M, Prcel P, Tern E